Advertisement

Injections de toxine botulique chez l’enfant IMC : stratégie multisites, évaluation multidimensionnelle, prises en charge associées

  • E. Chaléat-Valayer
  • J.-C. Bernard
  • É. Morel

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Gage JR (1991) Gait analysis in cerebral palsy clinics. London: Mac Keith PressGoogle Scholar
  2. 2.
    Chaléat-Valayer E, Vial C (2002) Mode d’action de la toxine botulique. Spasticité; 4: 17.SGoogle Scholar
  3. 3.
    Meunier FA, Schiavo G, Molgo J (2002) Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris; 96(1–2): 105–13PubMedGoogle Scholar
  4. 4.
    Molenaers G, Desloovere K, Eyssen M, De Cat J, Jonkers I, De Cock P (1999). Botulinum toxin type A treatment of cerebral palsy: an integrated approach. Eur J Neurol; 6(suppl 4): S51–S57Google Scholar
  5. 5.
    Boyd R, Graham HK (1997) Botulinum toxin A in the management of children with cerebral palsy: indication and outcome. Eur J Neurol; 4(suppl 2): S15–S22Google Scholar
  6. 6.
    Lee LR, Chuang YC (2004). Botulinum toxin for lower limb spasticity in children with CP a single blinded trial comparing dilution techniques. Am J Phys Med Rehabil; 83(10): 766–73PubMedGoogle Scholar
  7. 7.
    Boyd RN, Graham HK (1999) Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol; 6(suppl 4): S23–S35Google Scholar
  8. 8.
    Rodda J, Graham HK (2001) Classification of gait patterns in spastic hemiplegia and spastic diplegia: a basis for a management algorithm. Eur J Neurol; 8(suppl 5): 98–108PubMedGoogle Scholar
  9. 9.
    Noonan KJ, Halliday S, Browne R et al. (2003) Interobserver variability of gait analysis in patients with cerebral palsy. J Pediatr Orthop; 23(3): 279–87CrossRefPubMedGoogle Scholar
  10. 10.
    Lord SE, Halligan PW, Wade DT (1998). Visual gait analysis: the development of a clinical assessment and scale. Clin Rehabil; 12(2): 107–19CrossRefPubMedGoogle Scholar
  11. 11.
    Mackey AH, Lobb GL, Walt SE et al. (2003) Reliability and validity of the Observational Gait Scale in children with spastic diplegia. Dev Med Child Neurol; 45(1): 4–11PubMedGoogle Scholar
  12. 12.
    Boyd RN, Graham H (1999) Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol; 6(suppl 4): S23–S35Google Scholar
  13. 13.
    Read HS, Hazlewood ME, Hillman SJ et al. (2003) Edinburgh visual gait score for use in cerebral palsy. J Pediatr Orthop; 23(3): 296–301CrossRefPubMedGoogle Scholar
  14. 14.
    Chaléat-Valayer E, Bernard JC, Schneider M et al. (2004) Intérêt de l’examen vidéographique dans l’analyse des résultats des injections de toxine botulinique au niveau des membres inférieurs chez l’enfant IMC. Lettre Med Phys Réadapt; (70): 20–2Google Scholar
  15. 15.
    Morel E, Bernard JC, Chaléat-Valayer E et al. (2004) Injections multisites de toxine botulique chez l’enfant Infirme Moteur Cérébral: rééducation et appareillage (à partir de l’expérience du service enfants du Centre des Massues). Kinésither Ann; (32–33): 28–36Google Scholar
  16. 16.
    Bell K J, Ounpuu S, DeLuca P et al. (2002) Natural Progression of gait in children with cerebral palsy. J Pediatr Orthop; 22(5): 677–82CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2005

Authors and Affiliations

  • E. Chaléat-Valayer
    • 1
  • J.-C. Bernard
    • 1
  • É. Morel
    • 1
  1. 1.Service enfants-adolescentsCentre médico-chirurgical de réadaptation des MassuesLyon Cedex 05

Personalised recommendations